BFPET

Drug Profile

BFPET

Alternative Names: 18-F FTPP; BFPET; BFPET (18)F-TPP

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Harvard Medical School; Massachusetts General Hospital
  • Developer FluoroPharma
  • Class Imaging agents; Organophosphorus compounds
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Coronary artery disease

Most Recent Events

  • 31 Mar 2017 Phase I development for Coronary artery disease (Diagnosis) is ongoing USA (IV)
  • 31 Mar 2017 FluoroPharma has patent protection for the composition and method of use of 18-F FCPHA and 18-F FTPP technologies
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis, In volunteers) in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top